Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians in Heart Failure

Summary

The goal of this study is improve the screening of heart failure and identify patients early who are at risk of heart failure.

The main question\[s\] it aims to answer are:

• will an electronic health records (EHR) case finding algorithm for heart failure, followed by N-Terminal pro-brain natriuretic peptide (NT-proBNP) screening and artificial intelligence (AI) echocardiogram compared to usual care identify patients at risk for heart failure earlier than standard of care?

Participants will be enrolled and randomized to either standard of care (SOC) or intervention arm:

SOC arm: electronic health records will be reviewed over six months for assessments performed to identify heart failure.

Intervention arm: blood sample for N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) at local laboratory . For elevated NT-proBNP results (\>125pg/ml) an artificial intelligence (AI) echocardiogram and 12 lead electrocardiogram (ECG) will be performed at study site (within 28 days of NT-proBNP result). EHR will be reviewed at six months

Conditions

• Heart Failure

Interventions

DIAGNOSTIC_TEST

NT-proBNP

blood sample to measure N-terminal prohormone of B-type natriuretic peptide at local laboratory

DIAGNOSTIC_TEST

AI echocardiogram

Artificial intelligence driven transthoracic echocardiogram

DIAGNOSTIC_TEST

electrocardiogram

tracing of electrical cardiac activity of the heart

OTHER

Cardiovascular physical examination

basic physiological measurements to include height (cm), weight (kg) and hip circumference (cm) and blood pressure (mmHg)

Sponsors & Collaborators

• AstraZeneca

  collaborator INDUSTRY

• Centre for Cardiovascular Innovation

  collaborator UNKNOWN

• NHS Greater Glasgow & Clyde

  collaborator UNKNOWN

• HeartLife Foundation

  collaborator UNKNOWN

• Canadian Heart Function Alliance

  collaborator UNKNOWN

• Montreal Heart Institute

  collaborator OTHER

• Cardiology Research UBC

  lead OTHER

Principal Investigators

• Nathaniel M Hawkins, MD · Associate Professor of Medicine, UBC Division of Cardiology

• Anique Ducharme, MD · Professor of Medicine, Univeriste de Montreal, Montreal Heart Institute

• Serge LePage, MD · Centre Hospitalier Universite de Sherbrooke-Hopital Fleurimont

Study Design

Allocation

RANDOMIZED

Purpose

SCREENING

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

40 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-03-01

Primary Completion

2027-01-01

Completion

2029-01-01

Countries

• Canada

Study Locations